Dr Reddy's Laboratories Ltd has informed the BSE about the audit of API manufacturing plant at Miryalguda near Hyderabad by the US FDA and certain observations on the plant.

Following the completion of the audit on Tuesday, the Hyderabad-based pharma company in a statement said, “We have been issued a form 483 with three observations, which we are addressing.”